Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARQIBO KIT vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after two or more anti-leukemia therapies
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic metabolism via CYP3A4; also undergoes biliary excretion.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 75% bound to plasma proteins, primarily to albumin and beta-globulins.
Approximately 85-90% bound to serum albumin.
Volume of distribution (Vd) is 4.0-7.9 L/kg (mean 5.6 L/kg), indicating extensive tissue binding and distribution into tissues, consistent with its lipophilic nature.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Not applicable; Marqibo is administered intravenously only. Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and P-glycoprotein efflux.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No specific dose adjustment guidelines. Use caution in patients with creatinine clearance <50 m L/min due to potential for increased exposure.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh B), reduce dose to 1.8 mg/m2 every 7 days. Mild impairment (Child-Pugh A): no adjustment necessary.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established in patients <18 years. Data limited to case reports; no standard dosing guidelines available.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment based on age alone. Monitor closely for increased toxicity (e.g., neurotoxicity, myelosuppression) due to potential for decreased organ function and comorbidities.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
MARQIBO is for intravenous use only. Fatal if given intrathecally. Use only with a medical provider experienced in the administration of chemotherapeutic agents. Contains vincristine sulfate, a vesicant. Ensure proper administration technique.
None.
Extensive extravasation precautions required; neurotoxicity (peripheral neuropathy, autonomic neuropathy); hematologic toxicity (myelosuppression); gastrointestinal toxicity (constipation, ileus); hepatic impairment; monitor serum uric acid levels; embryo-fetal toxicity.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to vincristine or any component of the formulation; patients with demyelinating conditions (e.g., Charcot-Marie-Tooth syndrome); intrathecal administration.
Hypersensitivity to AURLUMYN or any of its components.
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 and alter drug levels. Avoid St. John's wort as it may induce CYP3A4 and reduce efficacy. No specific food restrictions other than these. Maintain adequate hydration to prevent tumor lysis syndrome.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data on presence in human milk. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, discontinue breastfeeding during treatment and for at least 2 weeks after last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No established dose adjustments for pregnancy due to lack of studies. Pharmacokinetic changes (increased volume of distribution, decreased clearance) may necessitate dose modifications based on tolerability and response. Use lowest effective dose.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
MARQIBO KIT (vincristine sulfate liposome injection) is indicated for adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory acute lymphoblastic leukemia (ALL). It is a liposomal formulation of vincristine that prolongs drug exposure and enhances tumor delivery. Administer intravenously over 1 hour at a dose of 2.25 mg/m² without a maximum dose cap, unlike standard vincristine. Do not substitute for other vincristine formulations. Monitor for neurotoxicity, including peripheral neuropathy, autonomic neuropathy (constipation, ileus), and cranial nerve palsies. Premedicate with corticosteroids and antiemetics. Avoid concomitant use of strong CYP3A4 inducers or inhibitors due to altered metabolism. Neurotoxicity is dose-limiting and may require dose reduction or discontinuation. Tumor lysis syndrome may occur; ensure adequate hydration and allopurinol. Pregnancy category D; verify pregnancy status. Extravasation management is similar to other vinca alkaloids (apply heat, hyaluronidase).
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This medication is a form of chemotherapy given intravenously for a type of leukemia.,It may cause nerve damage; report numbness, tingling, pain, weakness, or constipation immediately.,Do not receive any live vaccines during treatment and for 6 months after.,Use effective contraception during treatment and for at least 1 month after the last dose.,Avoid grapefruit juice and St. John's wort while on this medication.,Drink plenty of fluids to prevent tumor lysis syndrome.,Report any signs of infection (fever, chills) or bleeding (easy bruising, black stools).
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARQIBO KIT vs AURLUMYN, answered by our medical review team.
MARQIBO KIT is a Antineoplastic Agent that works by Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARQIBO KIT and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARQIBO KIT is: 2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARQIBO KIT and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARQIBO KIT is classified as Category C. Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.